Clinical trials: Bird Flu
H7N9 Influenza
A Clinical Trail Of An Adjuvanted Inactivated H7N9 Influenza Vaccine
The aim of this study is to investigate the immunogenicity and safety of the inactivated whole-virion vaccine for teenagers and adults.
- Trial name
- NCT03369808
- Testing
- 7.5μg H7N9 Vaccine, Phosphate Buffer Solution, Aluminum Hydroxide Adjuvant
- Where
- China
- Volunteers
- 360 people, healthy volunteers welcome
- Sponsor
- Shanghai Institute Of Biological Products
Influenza
T and B Cell Response to Avian Flu Vaccine
The purpose of this substudy study is to evaluate the types of cells involved in fighting infection to the A/H5N1 (avian flu virus) vaccine.
- Trial name
- NCT00337896
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
A Study in Healthy Adults to Assess Priming With Antigenically Mismatched Live Attenuated A/H7N3 Influenza Virus Vaccine Followed by Inactivated A/H7N9 Influenza Virus Vaccine
The purpose of this study is to assess priming with antigenically mismatched live attenuated A/H7N3 influenza virus vaccine followed by inactivated A/H7N9 influenza virus vaccine in healthy adults.
- Trial name
- NCT03581903
- Testing
- H7N3 pLAIV, H7N9 pIIV
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Randomized, Double Blinded, Placebo Control Clinical Trial of Pandemic Influenza Inactive Vaccine on Healthy Subjects
Based on pre-clinical trial data and principle of GCP, the objective of phase I clinical trial is to evaluate safety and immunogenicity of Pan-flu vaccine, an inactivated whole virion H5N1 vaccine with aluminium hydroxide…
- Trial name
- NCT00356798
- Testing
- an inactivated whole virion H5N1 vaccine, adjuvanted
- Where
- China
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- Sinovac Biotech Co., Ltd
Influenza
H5N1 Vaccine Intramuscular Versus Intradermal in Healthy Adults
The purpose of this research study is to compare how the body reacts to different strengths of an H5N1 flu vaccine when given by different routes of injection (injection into the skin or into the muscle).
- Trial name
- NCT00310206
- Testing
- Inactivated Influenza A Vaccine A/H5N1
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza A Virus Infection, Influenza A
The Study of the Safety, Reactogenicity and Immunogenicity of the GamFluVac
The present clinical phase I study designed to examine the safety, reactogenicity and immunogenicity of the medicinal product - Vaccine vector against influenza A - in healthy volunteers after a single dose in the three groups…
- Conditions
- Influenza A Virus Infection, Influenza A, Influenza Epidemic, Influenza H5N1
- Trial name
- NCT03651544
- Testing
- GamFluVac
- Where
- Russia
- Volunteers
- 36 people, healthy volunteers welcome
- Sponsor
- Gamaleya Research Institute of Epidemiology and Microbiology, Health Ministry of the Russian Federation
Influenza
A Phase 1 Study to Evaluate the Immunogenicity and Safety of a Pandemic Avian Influenza Vaccine in Adults
Recombinant hemagglutinin has been shown to induce protective neutralising antibodies against avian influenza virus but is relatively non-immunogenic.
- Trial name
- FLU003 (NCT02335164)
- Testing
- recombinant influenza hemagglutinin, Advax1, Advax2
- Where
- Australia
- Volunteers
- 270 people, healthy volunteers welcome
- Sponsor
- Vaxine Pty Ltd
Influenza A Virus, H5N1 Subtype
Systems Biology of Influenza A (H5N1) Virus Monovalent Vaccine With and Without Adjuvant System 03 (AS03)
This study will compare the different immune responses to Influenza A (H5N1) Virus Monovalent Vaccine with and without the AS03 adjuvant.
- Trial name
- NCT01910519
- Testing
- H5N1 vaccine plus AS03 adjuvant, H5N1 vaccine without adjuvant
- Where
- United States
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza, Human, Influenza in Birds
A Study to Evaluate Safety and Immunogenicity of One or Two Booster Vaccinations With H5N6 Influenza Vaccine in Adults Primed With H5N1 Influenza Vaccine or Unprimed
This is a Phase 2, randomized, multi-center study in approximately 300 adults who received 2 doses of aH5N1c or placebo in and completed the parent study V89_18 in the <65 years of age cohort.
- Conditions
- Influenza, Human, Influenza in Birds, Respiratory Tract Infections, Infections
- Trial name
- NCT05422326
- Testing
- aH5N6c on Day 1, aH5N6c on Day 22
- Where
- 18 sites in United States
- Volunteers
- 260 people, healthy volunteers welcome
- Sponsor
- Seqirus
Avian Influenza
H5N8 Mix and Match With or Without AS03 or MF59 in Healthy Adults: Immunology
This is a Phase I cohort-randomized, double-blind, controlled trial designed to assess the safety, reactogenicity, and immunogenicity of a monovalent inactivated influenza A/H5N8 virus vaccine administered at different dosages…
- Trial name
- NCT03014310
- Testing
- AS03, MF59, Monovalent Influenza A/H5N8 vaccine
- Where
- 7 sites in United States
- Volunteers
- 388 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Immune Responses to H5N1 Vaccine With and Without AS03 Adjuvant
Background: Adjuvants are substances included in vaccines that stimulate the immune system and increase the body's response to the vaccine. The AS03 adjuvant is used in seasonal flu vaccines in Europe.
- Trial name
- NCT01578317
- Testing
- H5N1 vaccine plus AS03 adjuvant, H5N1 vaccine without adjuvant
- Where
- United States
- Volunteers
- 43 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Influenza
Immunogenicity and Safety of Pandemic Influenza Vaccines in Adults Aged 18 - 49 Years Old
This study will assess safety and immunogenicity of GSK Biologicals' H5N1 flu candidate vaccines GSK2590066A and GSK2340273A in healthy adults 18 - 49 years old.
- Trial name
- NCT01236040
- Testing
- GSK Biologicals' investigational vaccine GSK2590066A, GSK Biologicals' investigational vaccine GSK2592984A, GSK Biologicals' investigational vaccine GSK2340274A
- Where
- 4 sites in United States
- Volunteers
- 521 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Preventive Avian Flu
Phase I Safety and Immunogenicity of Live Attenuated Influenza H5 Candidate Vaccine Strain A/17/Turkey/Turkey/05/133 (H5N2) in Healthy Thai Volunteers
The purpose of this study is to evaluate safety and reactogenicity of live attenuated influenza H5 vaccine candidate strain A/17/turkey/Turkey/05/133 (H5N2) manufactured by GPO, in Thailand to previously healthy Thais.
- Trial name
- NCT01656356
- Testing
- Avian Flu Vaccine
- Where
- Thailand
- Volunteers
- healthy volunteers welcome
- Sponsor
- Mahidol University
Pandemic Influenza
Immunogenicity and Safety of Pandemic Influenza Vaccine in Healthy Adults
The objectives of this single arm study are to evaluate the immune response and safety profiles of two injections of an inactivated whole-virion vaccine containing aluminum hydroxide adjuvant, AdimFlu-W (H5N1), against influenza…
- Trial name
- NCT01640691
- Testing
- Pandemic Influenza Vaccine (H5N1)
- Where
- Taiwan
- Volunteers
- 39 people, healthy volunteers welcome
- Sponsor
- Adimmune Corporation
Influenza, Orthomyxoviridae Infections
Safety and Immunogenicity of 2 Formulations of an Intramuscular A/H5N1 Pandemic Influenza Vaccine in Children
This is an open, randomized, multicenter clinical trial. Objectives: To describe the safety profiles during the 21 days following each primary and booster injection.
- Conditions
- Influenza, Orthomyxoviridae Infections, Influenza A Virus Infection
- Trial name
- NCT00491985
- Testing
- A/H5N1 Inactivated, split-virion pandemic influenza vaccine, A/H5N1 Inactivated, split virion pandemic influenza vaccine
- Where
- Thailand
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Influenza Vaccines
Monovalent H5N1 Vaccine GSK1557484A in Children 6 Months to < 18 Years of Age
This study will assess safety and immunogenicity of GSK Biologicals' H5N1 flu candidate vaccine GSK1557484A in children 6 months to < 18 years of age.
- Trial name
- NCT01310413
- Testing
- Influenza A (H5N1) Virus monovalent vaccine
- Where
- 17 sites in United States, Canada and 1 more
- Volunteers
- 842 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Booster Trial to 07-0019 With A/Anhui/05 With and Without MF59
This research will study safety and the body's immune (defense system) responses, including anti-H5 flu antibodies (the body's protective proteins found in the blood), to an inactivated influenza "H5" bird flu, virus vaccine.
- Trial name
- NCT00912496
- Testing
- MF-59, A/Anhui/05
- Where
- 10 sites in United States
- Volunteers
- 637 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Phase 1 Safety Study of GelVac Nasal Powder H5N1 Influenza Vaccine
Study to Assess Safety of an Inactivated H5N1 Influenza Vaccine Administered in GelVac Nasal Powder to Healthy Young Adults
This is a double-blind, placebo controlled, safety and immunogenicity study of GelVac™ nasal powder H5N1 influenza vaccine. Healthy male and female subjects between 18 and 49 years of age who are eligible for study participation…
- Trial name
- NCT01258062
- Testing
- GelVac™ nasal powder H5N1 influenza vaccine.
- Where
- United States
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- Alachua Government Services, Inc.
Influenza
A Dose Ranging Safety and Immunogenicity Study of GlaxoSmithKline (GSK) Biologicals' GSK1557484A Vaccine in Children 6 to Less Than 36 Months of Age
The purpose of this study is to assess the safety and immunogenicity of different formulations of GSK Biologicals' influenza candidate vaccine GSK1557484A, in children 6-35 months of age.
- Trial name
- NCT02719743
- Testing
- Influenza A (H5N1) Virus monovalent vaccine (GSK1557484A).
- Where
- 7 sites in Taiwan, Thailand
- Volunteers
- 185 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine(s) GSK3206641A and GSK3206640A Administered in Adults 18 to 64 Years of Age
The purpose of this study is to evaluate the safety and immunogenicity of different formulations of GSK Biologicals' H7N9 influenza vaccine in subjects 18 to 64 years of age.
- Trial name
- NCT01999842
- Testing
- Investigational H7N9 vaccine GSK3206641A, Investigational H7N9 vaccine GSK3206640A
- Where
- 8 sites in United States, Canada
- Volunteers
- 424 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline